Pulse Biosciences director Duggan buys $13M in stock

Pulse Biosciences director Robert W. Duggan acquired $13,000,000 of company stock on May 15, 2026, in an open-market transaction. It was reported by investing.com on 15 May 2026 that the purchase was disclosed in an SEC filing. The filing names Duggan as a company director and shows the transaction value as $13,000,000. This piece summarizes what the filing says, the reporting mechanics, and immediate market considerations.

Who is Robert W. Duggan and what did he buy?

Robert W. Duggan is listed as a director of Pulse Biosciences and executed an open-market purchase valued at $13,000,000 on May 15, 2026. The disclosure shows Duggan acting in a personal capacity rather than as part of a firm or plan. The company is identified by its corporate name in the filing and the transaction is presented as a straightforward buy rather than a compensation grant.

The filing indicates the trade was reported to the SEC under standard insider-reporting rules. The single-line valuation in the filing lists $13,000,000 as the total purchase amount. Investors tracking executive activity use this figure to size the trade relative to company liquidity.

How large was the purchase and how was it executed?

The filing records a $13,000,000 open-market acquisition on May 15, 2026. The disclosure does not label the purchase as part of a pre-arranged trading plan in the text of the report available in public filings. The buyer is identified by name and title; the filing lists the trade as an ordinary secondary-market purchase rather than a private block.

Open-market buys of this size typically involve multiple executions across a single session or several sessions to limit market impact. The form shows a single transaction date but does not itemize every execution or per-share price in the public summary line.

What does the SEC filing show and when is it required?

Insider purchases are reported on SEC Form 4, which must be filed within two business days of the transaction date. The duggan transaction was reported on a filing dated May 15, 2026, consistent with the two-business-day rule. The Form 4 entry lists the director, transaction date, transaction type and aggregate purchase value of $13,000,000.

The Form 4 is publicly accessible on SEC EDGAR and is the definitive disclosure for timing and the identity of the buyer. For readers tracking regulatory paperwork or cross-checking claims, see company filings and standard insider filings resources for archived copies.

What are immediate market considerations and risks?

A $13,000,000 director buy is material for watchlists but does not change company fundamentals by itself. The trade size relative to outstanding float determines price impact; the filing lists only the dollar amount, not the percent of free float. Market participants should note that director buys can be reversed through later sales, and ownership changes via secondary sales or dilution are possible.

Reporting rules and blackout periods can limit when insiders transact; the public filing does not explain motive. Investors must not treat an insider purchase as a guarantee of future performance. For methodology on interpreting such trades, consult our insider trades resources.

Q? How quickly must insiders report purchases to the SEC?

Under SEC rules, insiders must file Form 4 within two business days after the transaction date. The Form 4 specifies the transaction type, date, number of shares or derivative changes, and aggregate transaction value. Filings appear on SEC EDGAR and are commonly mirrored by market data services within 24 hours after submission, enabling timely third-party flagging of buys like the $13,000,000 Duggan trade.

Q? Does a director purchase signal the company will perform better?

A director purchase signals personal capital allocation by that insider but is not a certainty of future company performance. Regulatory filings do not reveal intent or private information. Insiders can buy for diversification, tax planning, or other reasons unrelated to near-term operational outcomes.

Bottom Line

A $13,000,000 open-market purchase by director Robert W. Duggan was reported on May 15, 2026 and disclosed via an SEC Form 4 filing.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.